Innate pockets $35 million from BMS for Phase I anticancer antibody

Innate Pharma is to receive $35 million up front having secured a global agreement for the development and commercialisation of IPH2102, a novel antibody in Phase I to treat cancer, with Bristol-Myers Squibb.